NX Prenatal
Louisville, US · Founded 2013 · Delaware corporation · 5 known investors
NX Prenatal is a molecular diagnostics company developing exosome-based liquid biopsy assays that detect adverse pregnancy conditions such as preterm birth, preeclampsia, and placenta accreta. Its non-invasive tests help physicians identify at-risk pregnancies to intervene and reduce complications for mother and child.
Founders & leadership
GP
GAIL PAGENamed on SEC filing
BB
BRIAN BROHMANNamed on SEC filing
RS
ROBERT SAUNDERSNamed on SEC filing
KB
KEVIN BRAMERNamed on SEC filing
AM
ALAN MACKNamed on SEC filing
Investors · 5
Reported raises · per SEC filings
Form D private placements$8.6M disclosed across 4 rounds · 2017–2023
▶$3.1MraisedAug 2023 · 20 investors · Other Health CareRule 506(b)
▶$3.1MraisedAug 2023 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT SAUNDERSDirector
- GAIL PAGEExecutive Officer, Director
- BRIAN BROHMANExecutive Officer
- DAVID ADAIRDirector
- ALAN MACKDirector
- Offering amount
- $15M
- Amount sold
- $3.1M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedAug 2021 · 47 investors · Other Health CareRule 506(b)
▶$5MraisedAug 2021 · 47 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Alan MackDirector
- Gail PageExecutive Officer, Director
- Brian BrohmanExecutive Officer, Director
- David AdairDirector
- Robert SaundersDirector
- Mary Lake PolanDirector
- Offering amount
- $6M
- Amount sold
- $5M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$72KraisedNov 2020 · 3 investors · Other Health CareRule 506(b)
▶$72KraisedNov 2020 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mary Lake PolanDirector
- Alan MackDirector
- Robert SaundersDirector
- David AdairDirector
- Gail PageExecutive Officer, Director
- Brian BrohmanExecutive Officer
- Offering amount
- $72K
- Amount sold
- $72K
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$427.5KraisedNov 2017 · 28 investors · Other Health CareRule 506(b)
▶$427.5KraisedNov 2017 · 28 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- GAIL PAGEExecutive Officer, Director
- BRIAN BROHMANExecutive Officer, Director
- ROBERT SAUNDERSDirector
- KEVIN BRAMERDirector
- ALAN MACKDirector
- Offering amount
- $1M
- Amount sold
- $427.5K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with NX Prenatal for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does NX Prenatal do?
- NX Prenatal is a molecular diagnostics company developing exosome-based liquid biopsy assays that detect adverse pregnancy conditions such as preterm birth, preeclampsia, and placenta accreta. Its non-invasive tests help physicians identify at-risk pregnancies to intervene and reduce complications for mother and child.
- Who are NX Prenatal's investors?
- NX Prenatal's investors include Belle Impact Fund, Mindshift Capital, Solas BioVentures, Golden Seeds, Portfolia.
- How much funding has NX Prenatal raised?
- NX Prenatal has disclosed $8.6M raised across 4 rounds.
- Where is NX Prenatal headquartered?
- NX Prenatal is headquartered in Louisville, US.